

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1 (currently amended): An isolated antibody which specifically binds to a polypeptide having at least 99% amino acid sequence identity to:

- (a) the amino acid sequence shown in Figure 8 (SEQ ID NO:8);
- (b) the amino acid sequence shown in Figure 8 (SEQ ID NO:8), lacking its associated signal peptide;
- (c) an amino acid sequence encoded by the nucleotide sequence shown in Figure 3 (SEQ ID NO:3);
- (d) an amino acid sequence encoded by the full-length coding sequence of the nucleotide sequence shown in Figure 3 (SEQ ID NO:3); or
- (e) an amino acid sequence encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209750.

2 (currently amended): The antibody of Claim 1 which specifically binds to a polypeptide comprising:

- (a) the amino acid sequence shown in Figure 8 (SEQ ID NO:8);
- (b) the amino acid sequence shown in Figure 8 (SEQ ID NO:8), lacking its associated signal peptide;
- (c) an amino acid sequence encoded by the nucleotide sequence shown in Figure 3 (SEQ ID NO:3);
- (d) an amino acid sequence encoded by the full-length coding sequence of the nucleotide sequence shown in Figure 3 (SEQ ID NO:3); or
- (e) an amino acid sequence encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209750.

3 (original): The antibody of Claim 1 which is a monoclonal antibody.

4 (original): The antibody of Claim 1 which is an antibody fragment.

5 (original): The antibody of Claim 1 which is a chimeric or a humanized antibody.

6 (original): The antibody of Claim 1 which is conjugated to a growth inhibitory agent.

7 (original): The antibody of Claim 1 which is conjugated to a cytotoxic agent.

8 (original): The antibody of Claim 7, wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

9 (original): The antibody of Claim 7, wherein the cytotoxic agent is a toxin.

10 (original): The antibody of Claim 9, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

11 (original): The antibody of Claim 9, wherein the toxin is a maytansinoid.

12 (original): The antibody of Claim 1 which is produced in bacteria.

13 (original): The antibody of Claim 1 which is produced in CHO cells.

14 (canceled)

15 (original): The antibody of Claim 1 which is detectably labeled.

16 (new): The antibody of Claim 2 which specifically binds to a polypeptide comprising the amino acid sequence shown in Figure 8 (SEQ ID NO:8).

17 (new): The antibody of Claim 2 which specifically binds to a polypeptide comprising the amino acid sequence shown in Figure 8 (SEQ ID NO:8), lacking its associated signal peptide.

18 (new): The antibody of Claim 2 which specifically binds to a polypeptide comprising an amino acid sequence encoded by the nucleotide sequence shown in Figure 3 (SEQ ID NO:3).

19 (new): The antibody of Claim 2 which specifically binds to a polypeptide comprising an amino acid sequence encoded by the full-length coding sequence of the nucleotide sequence shown in Figure 3 (SEQ ID NO:3).

20 (new): The antibody of Claim 2 which specifically binds to a polypeptide comprising an amino acid sequence encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209750.